IDH突变型2级胶质瘤唤醒定位术后恢复就业与总生存的相关性:515例连续病例系列
该连续队列纳入1997年6月至2023年9月由同一术者完成的515例术前在职的IDH突变型2级胶质瘤患者,均接受基于连接组学的唤醒定位引导切除。91.5%患者术后恢复就业,恢复就业与更高术前及术后KPS评分、更大切除程度、无早期辅助治疗及更长总生存相关(p=0.005)。
要点
- 唤醒定位引导切除后91.5%的IDH突变型2级胶质瘤患者可恢复就业。
- 恢复就业与更大切除程度、更好功能状态及更长总生存相关。
- 结果支持在保留就业能力目标下早期最大程度切除。
核心结论
- 唤醒定位引导切除IDH突变型2级胶质瘤后恢复就业与更好功能状态、更大切除程度、更高再手术可能性及更长总生存显著相关,且不受肿瘤位置和分子分型影响。
研究设计与样本
- 研究为连续队列研究,纳入1997年6月至2023年9月由同一作者完成的基于连接组学唤醒手术前瞻性数据库中的515例患者(292例男性,平均年龄36.8±9.2岁)。
- 纳入标准为术前在职且术后随访≥2年的IDH突变型2级胶质瘤患者,比较术后能恢复就业与不能恢复就业者。
主要发现
- 471例(91.5%)患者术后恢复就业,平均随访8.3±4.3年,总生存率为79.5%。
- 恢复就业与更高术前及术后KPS评分相关(p<0.0001),与更低术前(p=0.027)及术后(p=0.001)难治性癫痫比例相关。
- 恢复就业与更小术前(p=0.002)及术后(p=0.004)肿瘤体积、更大切除程度(p=0.0004)及未接受早期辅助治疗(p=0.013)相关。
- 恢复就业还与更高再手术率(p=0.026)及更长总生存(p=0.005)相关。
关键数值与推荐
- 术前平均KPS评分为95.7±5.4,术后平均KPS评分为94.4±6.2。
- 术前平均肿瘤体积为56.3±45.4 cm3,平均切除程度为91.8%±8.6%,超全/全切除164例(31.8%),平均残余肿瘤体积为5.8±8.1 cm3。
- 术后持续神经功能缺损4例(0.8%),术后持续难治性癫痫34例(6.6%)。
- 肿瘤类型为IDH突变型星形细胞瘤294例(57.1%),少突胶质细胞瘤221例(42.9%);接受早期辅助肿瘤治疗80例(15.5%),再手术161例(31.3%)。
临床怎么用
- 对于术前在职的IDH突变型2级胶质瘤患者,应在唤醒定位下争取早期最大程度切除,同时以保留就业能力为目标。
- 术后恢复就业可作为更好功能状态和更长生存的临床参考指标。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although the life expectancy after surgery for IDH-mutant grade 2 glioma (G2G) is now approximately 20 years, the resumption of postresection employment has received little attention. The aim of this study was to identify factors associated with return to work (RTW) following awake mapping-guided resection and its potential impact on long-term outcomes in a homogeneous cohort of patients with G2G. METHODS: Patients with G2G who were employed before surgery and had ≥ 2 years of postoperative follow-up were identified from a prospective database of connectome-based awake surgical cases performed by the author between June 1997 and September 2023. Patients who were able to RTW were compared with those who were unable to resume employment following surgery. RESULTS: This consecutive series included 515 patients (292 male, mean age 36.8 ± 9.2 years). Clinical presentation included 410 patients (79.6%) with epilepsy and 105 (20.4%) with incidental findings. Preoperatively, the mean Karnofsky Performance Scale (KPS) score was 95.7 ± 5.4 and mean tumor volume was 56.3 ± 45.4 cm3. Four patients (0.8%) experienced persistent postoperative neurological deficit. The mean postoperative KPS score was 94.4 ± 6.2, with persistent intractable epilepsy in 34 patients (6.6%). Moreover, 471 patients were able to RTW (91.5%). The mean extent of resection (EOR) was 91.8% ± 8.6%, with supratotal/total EOR in 164 patients (31.8%), and the mean residual tumor volume was 5.8 ± 8.1 cm3. The tumor type was IDH-mutant astrocytoma in 294 patients (57.1%) and oligodendroglioma in 221 (42.9%). Early adjuvant oncological treatment was administered in 80 patients (15.5%), and 161 patients (31.3%) underwent reoperation. The mean follow-up was 8.3 ± 4.3 years, with an overall survival (OS) rate of 79.5%. RTW was correlated with a higher KPS score before and after surgery (p < 0.0001), lower proportion of intractable seizures preoperatively (p = 0.027) and postoperatively (p = 0.001), smaller tumor volume before (p = 0.002) and after (p = 0.004) surgery, greater EOR (p = 0.0004), and absence of early adjuvant therapy (p = 0.013). Moreover, RTW was associated with a higher rate of reoperation (p = 0.026) and longer OS (p = 0.005). CONCLUSIONS: This is the first ever published consecutive cohort study demonstrating that RTW following awake mapping-guided resection of G2G was significantly correlated to better functional status, greater EOR, higher likelihood of further surgery, and prolonged OS, regardless of tumor location and molecular pattern. These findings support earlier and maximum resection, with the goal of preserving the capacity for employment because a more active lifestyle is associated with prolonged life expectancy.
引用
- Duffau H. Correlation between resumption of employment and overall survival following awake mapping-based surgery for IDH-mutant grade 2 glioma: a consecutive series with 515 patients. J Neurosurg. 2026. PMID: 42430801. doi:10.3171/2026.2.JNS252614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。